{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:51:28Z","timestamp":1790124688818,"version":"4.0.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:00:00Z","timestamp":1756080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:00:00Z","timestamp":1756080000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Ministry of Education, Science, and Culture, Japan","award":["17K08709"],"award-info":[{"award-number":["17K08709"]}]},{"name":"the Ministry of Education, Science, and Culture, Japan","award":["19K09834"],"award-info":[{"award-number":["19K09834"]}]},{"DOI":"10.13039\/100027084","name":"Sasaki Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100027084","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Human Cell"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Nicotinamide N-methyltransferase (NNMT) is an S-adenosyl-l-methionine (SAM)-dependent cytosolic enzyme, and a growing body of evidence suggest that it plays an essential role in cancer progression. Recently, NNMT has a role in methylation metabolism and tumorigenesis and was associated with a poor prognosis against numerous cancers. In addition, it has been reported that NNMT has been overexpressed in the stroma of advanced high-grade serous carcinoma and may contribute to decreased survival. This study aimed to identify novel biomarkers to predict resistance and investigate their clinicopathologic significance in paclitaxel-resistant advanced or recurrent ovarian clear cell carcinoma (OCCC). Fluorescence-labeled two-dimensional differential gel electrophoresis (2D-DIGE), immunohistochemical, and MASCOT analyses allowed us to identify the cytoplasmic metabolic enzyme NNMT. In cultured cell studies, NNMT protein expression was higher in paclitaxel-resistant OVMANA and OVTOKO cells than in paclitaxel-sensitive KK and ES-2 cells. Furthermore, although analysis of clinical tissue samples showed no association with poor prognosis in 7 individuals with low NNMT expression in the cytoplasm of OCCC cells, high expression of NNMT in the cytoplasm of OCCC cells may be associated with low sensitivity to paclitaxel in OCCC and may have prognostic implications. Therefore, targeting therapy to reduce cytoplasmic NNMT expression levels may increase the sensitivity of OCCC to paclitaxel.<\/jats:p>","DOI":"10.1007\/s13577-025-01282-z","type":"journal-article","created":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T13:40:29Z","timestamp":1756129229000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Nicotinamide N-methyltransferase enhances paclitaxel resistance in ovarian clear cell carcinoma"],"prefix":"10.1007","volume":"38","author":[{"given":"Ryoko","family":"Kikuchi-Koike","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Sasajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Miyagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Uozaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Umayahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Takasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chikara","family":"Kihira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruka","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Ichinose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mana","family":"Hirano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruko","family":"Hiraike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunori","family":"Nagasaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,25]]},"reference":[{"key":"1282_CR1","first-page":"7","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72:7\u201333.","journal-title":"CA Cancer J Clin"},{"key":"1282_CR2","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.ygyno.2021.06.033","volume":"162","author":"A Gadducci","year":"2021","unstructured":"Gadducci A, Multinu F, Cosio S, Carinelli S, Ghioni M, Aletti GD. Clear cell carcinoma of the ovary: epidemiology, pathological and biological features, treatment options and clinical outcomes. Gynecol Oncol. 2021;162:741\u201350.","journal-title":"Gynecol Oncol"},{"key":"1282_CR3","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ygyno.2020.10.014","volume":"160","author":"L Ceppi","year":"2021","unstructured":"Ceppi L, Grassi T, Galli F, et al. Early-stage clear cell ovarian cancer compared to high-grade histological subtypes: an outcome exploratory analysis in two oncology centers. Gynecol Oncol. 2021;160:64\u201370.","journal-title":"Gynecol Oncol"},{"key":"1282_CR4","first-page":"561","volume":"91","author":"SM Penny","year":"2020","unstructured":"Penny SM. Ovarian cancer: an overview. Radiol Technol. 2020;91:561\u201375.","journal-title":"Radiol Technol"},{"key":"1282_CR5","first-page":"1041","volume":"10","author":"D Sirichaisutdhikorn","year":"2009","unstructured":"Sirichaisutdhikorn D, Suprasert P, Khunamornpong S. Clinical outcome of the ovarian clear cell carcinoma compared to other epithelial ovarian cancers when treated with paclitaxel and carboplatin. Asian Pac J Cancer Prev. 2009;10:1041\u20135.","journal-title":"Asian Pac J Cancer Prev"},{"key":"1282_CR6","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1158\/1078-0432.CCR-08-1274","volume":"15","author":"D Aoki","year":"2009","unstructured":"Aoki D, Oda Y, Hattori S, et al. Overexpression of class III beta-tubulin predicts good response to taxane-based chemotherapy in ovarian clear cell adenocarcinoma. Clin Cancer Res. 2009;15:1473\u201380.","journal-title":"Clin Cancer Res"},{"key":"1282_CR7","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1186\/s12885-015-1744-5","volume":"15","author":"CM Ho","year":"2015","unstructured":"Ho CM, Huang CJ, Huang SH, Chang SF, Cheng WF. Demethylation of HIN-1 reverses paclitaxel-resistance of ovarian clear cell carcinoma through the AKT-mTOR signaling pathway. BMC Cancer. 2015;15:789.","journal-title":"BMC Cancer"},{"key":"1282_CR8","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2020.31.e94","volume":"31","author":"E Kondo","year":"2020","unstructured":"Kondo E, Tabata T, Suzuki N, et al. The post-progression survival of patients with recurrent or persistent ovarian clear cell carcinoma: results from a randomized phase III study in JGOG3017\/GCIG. J Gynecol Oncol. 2020;31: e94.","journal-title":"J Gynecol Oncol"},{"key":"1282_CR9","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1097\/CAD.0000000000001472","volume":"34","author":"K Ito","year":"2023","unstructured":"Ito K, Nakagawa M, Shimokawa M, et al. Phase II study of gemcitabine, cisplatin, and bevacizumab for first recurrent and refractory ovarian clear cell carcinoma Kansai Clinical Oncology Group-G1601. Anticancer Drugs. 2023;34:857\u201365.","journal-title":"Anticancer Drugs"},{"key":"1282_CR10","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1006\/gyno.1995.1097","volume":"57","author":"I Gorai","year":"1995","unstructured":"Gorai I, Nakazawa T, Miyagi E, et al. Establishment and characterization of two human ovarian clear cell adenocarcinoma lines from metastatic lesions with different properties. Gynecol Oncol. 1995;57:33\u201346.","journal-title":"Gynecol Oncol"},{"key":"1282_CR11","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1038\/bjc.1997.471","volume":"76","author":"T Yanagibashi","year":"1997","unstructured":"Yanagibashi T, Gorai I, Nakazawa T, et al. Complexity of expression of the intermediate filaments of six new human ovarian carcinoma cell lines: new expression of cytokeratin 20. Br J Cancer. 1997;76:829\u201335.","journal-title":"Br J Cancer"},{"key":"1282_CR12","first-page":"279","volume":"6","author":"H Sasa","year":"1993","unstructured":"Sasa H, Ishii K, Hirata J, et al. Establishment and characterization of a CA125-producing human ovarian clear cell carcinoma cell line. Hum Cell. 1993;6:279\u201386.","journal-title":"Hum Cell"},{"key":"1282_CR13","first-page":"426","volume":"1","author":"S Nozawa","year":"1988","unstructured":"Nozawa S, Tsukazaki K, Sakayori M, et al. Establishment of a human ovarian clear cell carcinoma cell line (RMG-I) and its single cell cloning\u2013with special reference to the stem cell of the tumor. Hum Cell. 1988;1:426\u201335.","journal-title":"Hum Cell"},{"key":"1282_CR14","first-page":"56","volume":"8","author":"CM Ho","year":"2018","unstructured":"Ho CM, Lee FK, Huang SH, Cheng WF. Everolimus following 5-aza-2-deoxycytidine is a promising therapy in paclitaxel-resistant clear cell carcinoma of the ovary. Am J Cancer Res. 2018;8:56\u201369.","journal-title":"Am J Cancer Res"},{"key":"1282_CR15","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1002\/path.6006","volume":"258","author":"JX Ji","year":"2022","unstructured":"Ji JX, Cochrane DR, Negri GL, et al. The proteome of clear cell ovarian carcinoma. J Pathol. 2022;258:325\u201338.","journal-title":"J Pathol"},{"key":"1282_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.883","volume":"12","author":"A Reustle","year":"2022","unstructured":"Reustle A, Menig LS, Leuthold P, et al. Nicotinamide-N-methyltransferase is a promising metabolic drug target for primary and metastatic clear cell renal cell carcinoma. Clin Transl Med. 2022;12: e883.","journal-title":"Clin Transl Med"},{"key":"1282_CR17","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1002\/path.5037","volume":"244","author":"JX Ji","year":"2018","unstructured":"Ji JX, Wang YK, Cochrane DR, Huntsman DG. Clear cell carcinomas of the ovary and kidney: clarity through genomics. J Pathol. 2018;244:550\u201364.","journal-title":"J Pathol"},{"key":"1282_CR18","doi-asserted-by":"publisher","first-page":"117474","DOI":"10.1016\/j.lfs.2020.117474","volume":"248","author":"F Ehebauer","year":"2020","unstructured":"Ehebauer F, Ghavampour S, Kraus D. Glucose availability regulates nicotinamide N-methyltransferase expression in adipocytes. Life Sci. 2020;248:117474.","journal-title":"Life Sci"},{"key":"1282_CR19","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1369\/0022155420976590","volume":"69","author":"L Zhang","year":"2021","unstructured":"Zhang L, Song M, Zhang F, et al. Accumulation of nicotinamide N-methyltransferase (NNMT) in cancer-associated fibroblasts: a potential prognostic and predictive biomarker for gastric carcinoma. J Histochem Cytochem. 2021;69:165\u201376.","journal-title":"J Histochem Cytochem"},{"key":"1282_CR20","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.3390\/biom12101487","volume":"12","author":"W Zhang","year":"2022","unstructured":"Zhang W, Jing Y, Wang S, et al. Identification of biological functions and prognostic value of NNMT in oral squamous cell carcinoma. Biomolecules. 2022;12:1487.","journal-title":"Biomolecules"},{"key":"1282_CR21","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1080\/01443615.2020.1732891","volume":"41","author":"\u0130 Harmankaya","year":"2021","unstructured":"Harmankaya \u0130, Akar S, U\u011fra\u015f S, et al. Nicotinamide N-methyltransferase overexpression may be associated with poor prognosis in ovarian cancer. J Obstet Gynaecol. 2021;41:248\u201353.","journal-title":"J Obstet Gynaecol"},{"key":"1282_CR22","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1756-9966-28-20","volume":"28","author":"J Kim","year":"2009","unstructured":"Kim J, Hong SJ, Lim EK, et al. Expression of nicotinamide N-methyltransferase in hepatocellular carcinoma is associated with poor prognosis. J Exp Clin Cancer Res. 2009;28:20.","journal-title":"J Exp Clin Cancer Res"},{"key":"1282_CR23","doi-asserted-by":"publisher","first-page":"3923","DOI":"10.1007\/s13277-013-0980-z","volume":"34","author":"KT Win","year":"2013","unstructured":"Win KT, Lee SW, Huang HY, et al. Nicotinamide N-methyltransferase overexpression is associated with Akt phosphorylation and indicates worse prognosis in patients with nasopharyngeal carcinoma. Tumour Biol. 2013;34:3923\u201331.","journal-title":"Tumour Biol"},{"key":"1282_CR24","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s13058-019-1150-z","volume":"21","author":"Y Wang","year":"2019","unstructured":"Wang Y, Zeng J, Wu W, et al. Nicotinamide N-methyltransferase enhances chemoresistance in breast cancer through SIRT1 protein stabilization. Breast Cancer Res. 2019;21:64.","journal-title":"Breast Cancer Res"},{"key":"1282_CR25","doi-asserted-by":"publisher","first-page":"45837","DOI":"10.18632\/oncotarget.9962","volume":"7","author":"X Xie","year":"2016","unstructured":"Xie X, Liu H, Wang Y, et al. Nicotinamide N-methyltransferase enhances resistance to 5-fluorouracil in colorectal cancer cells through inhibition of the ASK1-p38 MAPK pathway. Oncotarget. 2016;7:45837\u201348.","journal-title":"Oncotarget"},{"key":"1282_CR26","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/s41586-019-1173-8","volume":"569","author":"MA Eckert","year":"2019","unstructured":"Eckert MA, Coscia F, Chryplewicz A, et al. Proteomics reveals NNMT as a master metabolic regulator of cancer-associated fibroblasts. Nature. 2019;569:723\u20138.","journal-title":"Nature"},{"key":"1282_CR27","doi-asserted-by":"publisher","first-page":"2699","DOI":"10.1016\/j.drudis.2021.05.011","volume":"26","author":"Y Gao","year":"2021","unstructured":"Gao Y, Martin NI, van Haren MJ. Nicotinamide N-methyl transferase (NNMT): an emerging therapeutic target. Drug Discov Today. 2021;26:2699\u2013706.","journal-title":"Drug Discov Today"}],"container-title":["Human Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13577-025-01282-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13577-025-01282-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13577-025-01282-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T08:28:11Z","timestamp":1757147291000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13577-025-01282-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,25]]},"references-count":27,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["1282"],"URL":"https:\/\/doi.org\/10.1007\/s13577-025-01282-z","relation":{},"ISSN":["1749-0774"],"issn-type":[{"value":"1749-0774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,25]]},"assertion":[{"value":"31 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Approval of the research protocol by the Institutional Ethics Committee of the Medical Faculty at Teikyo University (13-003-4, 22 October 2020).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from all the patients for the use of their samples and collection in research.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"151"}}